UK Clinical Trial Numbers Still ‘Buoyant’ After Brexit
MHRA Transformation Will 'Reshape And Reskill' Workforce
In this second article on the post-Brexit fortunes of the UK medicines regulator, the MHRA, Pink Sheet looks at the emergence of a new UK clinical trials environment, how the agency is facing up to resource pressures, and when the new fee structure might be ready.
You may also be interested in...
Industry Calls For Urgent Action As UK Drops In Global Ranking For Clinical Trials
The UK’s research-based industry association has issued a dire warning over the UK’s “deteriorating ability to attract and deliver industry clinical trials.”
New UK Drug Applications At ‘Sustained Levels’ Post-Brexit
The MHRA’s chief executive explains to the Pink Sheet how the agency will ensure the UK remains an attractive place to seek approval of new innovative drugs and build on the regulatory flexibilities introduced during the COVID-19 pandemic.
UK Regulator Calls For More Patient Involvement In Trial Design
UK plans for a flexible and streamlined clinical trial regulatory regime are now out for consultation, covering areas such as investigational medicinal products, greater patient involvement in trial design, and lighter-touch oversight of low-intervention trials.